Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The firm is updating its global biopharma coverage forecasts ahead of Q4 earnings following check-ins with investor relations teams and recent public commentary, the analyst tells investors in a preview for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
Questions or Comments about the article? Write to editor@tipranks.com